MeiraGTx Holdings plc Payments to Acquire in Process Research and Development
MeiraGTx Holdings plc (MGTX) reported Payments to Acquire in Process Research and Development of $24.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment · last filed 2026-08-13
- MeiraGTx Holdings plc payments to acquire in process research and development for the quarter ending 2026-06-30 was $23.98M.
- MeiraGTx Holdings plc payments to acquire in process research and development for the quarter ending 2026-03-31 was $250.00K.
- MeiraGTx Holdings plc payments to acquire in process research and development for fiscal 2025 was $410.00K.
| Period end | Payments to Acquire in Process Research and Development 3 month | Payments to Acquire in Process Research and Development 6 month | Payments to Acquire in Process Research and Development 12 month |
|---|---|---|---|
| 2026-06-30 | $23.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $24.23M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $250.00K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $410.00K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |